TIDMSAR
RNS Number : 5057S
Sareum Holdings PLC
12 March 2019
(AIM: SAR) 12 March 2019
SAREUM HOLDINGS PLC
("Sareum" or the "Company")
Issue of Options
The Company announces that it granted on 8 March 2019 the
following share options (the "Options") to Dr Tim Mitchell, Chief
Executive Officer, Dr John Reader, Chief Scientific Officer, Dr
Stephen Parker, Non-executive Chairman, Dr Michael Owen,
Non-executive Director and Mr Clive Birch, Non-executive
Director.
Drs Mitchell and Reader will each receive an option over
23,633,388 Shares, exercisable by no later than 07 March 2029 in
the case of 11,816,694 Shares at 0.7 pence, 5,908,347 Shares at
1.05 pence and 5,908,347 Shares at 1.4 pence per Share,
respectively.
Dr Parker will receive an option over 8,100,000 Shares,
exercisable by no later than 07 March 2029, in the case of
4,050,000 Shares at 0.7 pence, 2,025,000 Shares at 1.05 pence and
2,025,000 Shares at 1.4 pence per Share, respectively.
Dr Owen and Mr Birch will each receive an option over 2,857,143
Shares, exercisable by no later than 07 March 2029 in the case of
1,428,571 Shares at 0.7 pence, 714,286 Shares at 1.05 pence and
714,286 Shares at 1.4 pence per Share, respectively.
Following the grants of Options referred to above, the interests
of Directors in options over Shares will be as follows:
Director Share scheme Exercise No. of Shares Percentage
price (pence) under option of issued
share capital
Dr Tim Mitchell EMI 0.25 6,400,000 0.22%
EMI 0.26 6,153,846 0.21%
EMI 1.2 2,566,666 0.09%
EMI 0.6 4,752,000 0.17%
EMI 0.425 7,198,353 0.25%
EMI 0.59 5,340,862 0.19%
EMI 0.8 6,250,000 0.22%
EMI 1.2 3,125,000 0.11%
EMI 1.6 3,125,000 0.11%
Unapproved 0.825 9,548,844 0.33%
Unapproved 1.2375 4,774,422 0.17%
Unapproved 1.65 4,774,421 0.17%
Unapproved 0.7 11,816,694 0.41%
Unapproved 1.05 5,908,347 0.21%
Unapproved 1.4 5,908,347 0.21%
Dr John Reader EMI 0.25 6,400,000 0.22%
EMI 0.26 6,153,846 0.21%
EMI 1.2 2,566,666 0.09%
EMI 0.6 4,752,000 0.17%
EMI 0.425 7,198,353 0.25%
EMI 0.59 5,340,862 0.19%
EMI 0.8 6,250,000 0.22%
EMI 1.2 3,125,000 0.11%
EMI 1.6 3,125,000 0.11%
Unapproved 0.825 9,548,844 0.33%
Unapproved 1.2375 4,774,422 0.17%
Unapproved 1.65 4,774,421 0.17%
Unapproved 0.7 11,816,694 0.41%
Unapproved 1.05 5,908,347 0.21%
Unapproved 1.4 5,908,347 0.21%
Dr Stephen Parker Unapproved 0.8 5,000,000 0.17%
Unapproved 1.2 2,500,000 0.09%
Unapproved 1.6 2,500,000 0.09%
Unapproved 0.825 3,272,728 0.11%
Unapproved 1.2375 1,636,364 0.06%
Unapproved 1.65 1,636,363 0.06%
Unapproved 0.7 4,050,000 0.14%
Unapproved 1.05 2,025,000 0.07%
Unapproved 1.4 2,025,000 0.07%
Dr Michael Owen Unapproved 0.7 1,428,571 0.05%
Unapproved 1.05 714,286 0.02%
Unapproved 1.4 714,286 0.02%
Mr Clive Birch Unapproved 0.7 1,428,571 0.05%
Unapproved 1.05 714,286 0.02%
Unapproved 1.4 714,286 0.02%
For further information, please contact:
Sareum Holdings plc
Tim Mitchell 01223 497 700
WH Ireland Limited (Nominated Adviser)
Chris Fielding / James Sinclair-Ford 020 7220 1666
Hybridan LLP (Nominated Broker)
Claire Noyce 020 3764 2341
Citigate Dewe Rogerson (Media enquiries)
Shabnam Bashir/ Mark Swallow/ David
Dible 020 7638 9571
Notes for editors:
Sareum is a specialist drug development company delivering
targeted small molecule therapeutics, to improve the treatment of
cancer and autoimmune disease. The Company generates value through
licensing its candidates to international pharmaceutical and
biotechnology companies at the preclinical or early clinical trials
stage.
Sareum's leading clinical-stage programme, SRA737, a novel
Checkpoint kinase 1 (Chk1) inhibitor licensed to NASDAQ-listed
Sierra Oncology, is in Phase 2 clinical trials targeting ovarian
and other advanced cancers. The key role of Chk1 in cancer cell
replication and DNA damage repair suggests that SRA737 may have
broad application as a targeted therapy in combination with other
oncology and immune-oncology drugs in genetically defined
patients.
Sareum is also advancing internal programmes focused on distinct
dual tyrosine kinase 2 (TYK2) /Janus kinase 1 (JAK1) inhibitors
through preclinical development as therapies for autoimmune
diseases (SDC-1801) and cancers (SDC-1802). TYK2 and JAK1 have
roles in pro-inflammatory responses in autoimmune diseases (e.g.
psoriasis, rheumatoid arthritis, inflammatory bowel diseases and
lupus) and tumour cell proliferation in certain cancers (e.g.
T-cell acute lymphoblastic leukaemia and some solid tumours). The
Company is targeting first human clinical trials in each indication
in 2020.
The Company also has an Aurora+FLT3 inhibitor targeting
haematological cancers, which is at the preclinical development
stage.
Sareum Holdings plc is listed on the AIM market of the London
Stock Exchange, trading under the ticker SAR. For further
information, please visit www.sareum.co.uk
- Ends -
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCQFLFFKXFZBBD
(END) Dow Jones Newswires
March 12, 2019 03:00 ET (07:00 GMT)
Sareum (LSE:SAR)
Historical Stock Chart
From Apr 2024 to May 2024
Sareum (LSE:SAR)
Historical Stock Chart
From May 2023 to May 2024